Denied Entyvio? You Still Have Options.
Entyvio (vedolizumab) is a gut-selective biologic used for moderate to severe Crohn's disease and ulcerative colitis, and it's frequently targeted by insurance step therapy requirements. Most insurers require you to try and fail at least one (sometimes two) TNF inhibitors — like Humira or Remicade — before they'll approve Entyvio. Prior authorization requirements are strict, and documentation of previous treatment failures must be thorough. Even with a compelling clinical case, the initial review can result in a denial.
Option 1: Appeal Your Denial
If you've already tried TNF inhibitors and they didn't work, or if your doctor believes those medications are contraindicated for you, that is the heart of your appeal. A detailed letter of medical necessity that walks through your IBD history and prior treatment failures gives you a real shot at reversal. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Vedolizumab and gut-selective biologics are active areas of clinical research in inflammatory bowel disease. Trials may study Entyvio directly, biosimilars in development, or next-generation gut-targeted therapies. Eligible participants typically receive the study medication at no charge. Search ClinicalTrials.gov for "vedolizumab," "Crohn's disease," or "ulcerative colitis" to see what's currently enrolling near you.
Option 3: Patient Assistance Programs
Takeda, Entyvio's manufacturer, offers the Entyvio Access and Reimbursement Support program to help people navigate coverage challenges and access financial assistance. The Crohn's and Colitis Foundation (crohnscolitisfoundation.org) also connects people to financial support, case managers, and clinical trial resources specifically for IBD.
For a complete guide to Entyvio financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Entyvio.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Entyvio denied?
Entyvio is most often denied because of step therapy requirements — your insurer wants documented evidence that you've tried TNF inhibitors first (typically Humira or Remicade) and that they didn't work or weren't tolerated. It can also be denied due to incomplete prior authorization paperwork or missing documentation of your IBD diagnosis and severity. Your denial letter will identify the specific reason, which is your guide for the appeal.
Can I get Entyvio through a clinical trial?
Some clinical trials study vedolizumab directly for Crohn's disease or ulcerative colitis, and participants in approved trials typically receive the medication at no cost. There are also trials studying vedolizumab biosimilars and next-generation gut-selective therapies. Your gastroenterologist can help you evaluate whether a trial is appropriate for your situation. You can also search ClinicalTrials.gov for currently enrolling studies.
How long does an Entyvio appeal take?
Standard internal appeals are typically decided within 30 days. If your IBD is severe enough to qualify as medically urgent, your doctor can request expedited review — which must be decided within 72 hours. If your internal appeal fails, you can escalate to an independent external review, which generally takes up to 45 days. For inflammatory bowel disease, the stakes of delayed treatment are real — document urgency clearly with your gastroenterologist. Talk to your doctor before making any decisions about your treatment.